Similarly to recurrent BRAF mutations, non-canonical C>T, C>A, T>A, and T>C mutations in NRAS are 2.6- to 38-fold enriched within skin cancers compared with non-skin cancers (Figure S7). This evidence concerns the gene NRAS and skin cancer.